Anti-cytokine therapies for psoriasis

Experimental Cell Research

Volumn 317, Issue 9, 2011, Pages 1293-1300

  Nograles, Kristine E ^a   Krueger, James G ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Anti cytokine therapy; IL 12 23p40; IL 17; IL 23; Psoriasis; TNF

Indexed keywords

ABATACEPT; ABX IL8; ADALIMUMAB; AIN 457; ALEFACEPT; AMG 827; BRIAKINUMAB; CNTO 1959; CYTOKINE; CYTOKINE ANTIBODY; ETANERCEPT; ILV 095; IMMUNOMODULATING AGENT; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 12P40; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 23 P40; LY 2439821; NN 8226; PLACEBO; RECOMBINANT INTERLEUKIN 10; RECOMBINANT INTERLEUKIN 11; RECOMBINANT INTERLEUKIN 4; SCH 900222; SIFALIMUMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; USTEKINUMAB;

ARTHRALGIA; CLINICAL TRIAL (TOPIC); DENDRITIC CELL; DRUG EFFICACY; DRUG TARGETING; HEADACHE; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; INFLAMMATION; INJECTION SITE REACTION; KERATINOCYTE; LOADING DRUG DOSE; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; RESPIRATORY TRACT DISEASE; REVIEW; SEPSIS; SKIN DISEASE; T LYMPHOCYTE; TREATMENT RESPONSE; TUBERCULOSIS;

EID: 79955646735     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2011.01.024     Document Type: Review

References (68)

1. Christophers E. Psoriasis-epidemiology and clinical spectrum. Clin. Exp. Dermatol. 2001, 26:314-320.
2. Lowes M.A., Bowcock A.M., Krueger J.G. Pathogenesis and therapy of psoriasis. Nature 2007, 445:866-873.
3. Guttman-Yassky E., Krueger J.G. Psoriasis: evolution of pathogenic concepts and new therapies through phases of translational research. Br. J. Dermatol. 2007, 157:1103-1115.
4. Ellis C.N., Gorsulowsky D.C., Hamilton T.A., Billings J.K., Brown M.D., Headington J.T., Cooper K.D., Baadsgaard O., Duell E.A., Annesley T.M., et al. Cyclosporine improves psoriasis in a double-blind study. JAMA 1986, 256:3110-3116.
5. Jegasothy B.V., Ackerman C.D., Todo S., Fung J.J., Abu-Elmagd K., Starzl T.E. Tacrolimus (FK 506)-a new therapeutic agent for severe recalcitrant psoriasis. Arch. Dermatol. 1992, 128:781-785.
6. Gupta A.K., Fisher G.J., Elder J.T., Talwar H.S., Esmann J., Duell E.A., Nickoloff B.J., Voorhees J.J. Topical cyclosporine A inhibits the phorbol ester induced hyperplastic inflammatory response but not protein kinase C activation in mouse epidermis. J. Invest. Dermatol. 1989, 93:379-386.
7. Gottlieb S.L., Gilleaudeau P., Johnson R., Estes L., Woodworth T.G., Gottlieb A.B., Krueger J.G. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat. Med. 1995, 1:442-447.
8. Nestle F.O., Conrad C., Tun-Kyi A., Homey B., Gombert M., Boyman O., Burg G., Liu Y.J., Gilliet M. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J. Exp. Med. 2005, 202:135-143.
9. Zaba L.C., Krueger J.G., Lowes M.A. Resident and "inflammatory" dendritic cells in human skin. J. Invest. Dermatol. 2009, 129:302-308.
10. Lande R., Gregorio J., Facchinetti V., Chatterjee B., Wang Y.H., Homey B., Cao W., Su B., Nestle F.O., Zal T., Mellman I., Schroder J.M., Liu Y.J., Gilliet M. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 2007, 449:564-569.
11. Nguyen K.B., Watford W.T., Salomon R., Hofmann S.R., Pien G.C., Morinobu A., Gadina M., O'Shea J.J., Biron C.A. Critical role for STAT4 activation by type 1 interferons in the interferon-gamma response to viral infection. Science 2002, 297:2063-2066.
12. Santini S.M., Lapenta C., Logozzi M., Parlato S., Spada M., Di Pucchio T., Belardelli F. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J. Exp. Med. 2000, 191:1777-1788.
13. Bissonnette R., Papp K., Maari C., Yao Y., Robbie G., White W.I., Le C., White B. A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti-interferon-alfa monoclonal antibody, in subjects with chronic psoriasis. J. Am. Acad. Dermatol. 2010, 62:427-436.
14. Zaba L.C., Fuentes-Duculan J., Eungdamrong N.J., Abello M.V., Novitskaya I., Pierson K.C., Gonzalez J., Krueger J.G., Lowes M.A. Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J. Invest. Dermatol. 2009, 129:79-88.
15. Zaba L.C., Fuentes-Duculan J., Eungdamrong N.J., Johnson-Huang L.M., Nograles K.E., White T.R., Pierson K.C., Lentini T., Suarez-Farinas M., Lowes M.A., Krueger J.G. Identification of TNF-related apoptosis-inducing ligand and other molecules that distinguish inflammatory from resident dendritic cells in patients with psoriasis. J. Allergy Clin. Immunol. 2010, 125:1261-1268. e1269.
16. Lowes M.A., Chamian F., Abello M.V., Fuentes-Duculan J., Lin S.L., Nussbaum R., Novitskaya I., Carbonaro H., Cardinale I., Kikuchi T., Gilleaudeau P., Sullivan-Whalen M., Wittkowski K.M., Papp K., Garovoy M., Dummer W., Steinman R.M., Krueger J.G. Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc. Natl Acad. Sci. USA 2005, 102:19057-19062.
17. Zaba L.C., Cardinale I., Gilleaudeau P., Sullivan-Whalen M., Suarez-Farinas M., Fuentes-Duculan J., Novitskaya I., Khatcherian A., Bluth M.J., Lowes M.A., Krueger J.G. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J. Exp. Med. 2007, 204:3183-3194.
18. Manetti R., Parronchi P., Giudizi M.G., Piccinni M.P., Maggi E., Trinchieri G., Romagnani S. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J. Exp. Med. 1993, 177:1199-1204.
19. Oppmann B., Lesley R., Blom B., Timans J.C., Xu Y., Hunte B., Vega F., Yu N., Wang J., Singh K., Zonin F., Vaisberg E., Churakova T., Liu M., Gorman D., Wagner J., Zurawski S., Liu Y., Abrams J.S., Moore K.W., Rennick D., de Waal-Malefyt R., Hannum C., Bazan J.F., Kastelein R.A. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000, 13:715-725.
20. Aggarwal S., Ghilardi N., Xie M.H., de Sauvage F.J., Gurney A.L. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 2003, 278:1910-1914.
21. Lee E., Trepicchio W.L., Oestreicher J.L., Pittman D., Wang F., Chamian F., Dhodapkar M., Krueger J.G. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J. Exp. Med. 2004, 199:125-130.
22. Nair R.P., Ruether A., Stuart P.E., Jenisch S., Tejasvi T., Hiremagalore R., Schreiber S., Kabelitz D., Lim H.W., Voorhees J.J., Christophers E., Elder J.T., Weichenthal M. Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. J. Invest. Dermatol. 2008, 128:1653-1661.
23. Nair R.P., Duffin K.C., Helms C., Ding J., Stuart P.E., Goldgar D., Gudjonsson J.E., Li Y., Tejasvi T., Feng B.J., Ruether A., Schreiber S., Weichenthal M., Gladman D., Rahman P., Schrodi S.J., Prahalad S., Guthery S.L., Fischer J., Liao W., Kwok P.Y., Menter A., Lathrop G.M., Wise C.A., Begovich A.B., Voorhees J.J., Elder J.T., Krueger G.G., Bowcock A.M., Abecasis G.R. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat. Genet. 2009, 41:199-204.
24. Lowes M.A., Kikuchi T., Fuentes-Duculan J., Cardinale I., Zaba L.C., Haider A.S., Bowman E.P., Krueger J.G. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J. Invest. Dermatol. 2008, 128:1207-1211.
25. Nograles K.E., Zaba L.C., Guttman-Yassky E., Fuentes-Duculan J., Suarez-Farinas M., Cardinale I., Khatcherian A., Gonzalez J., Pierson K.C., White T.R., Pensabene C., Coats I., Novitskaya I., Lowes M.A., Krueger J.G. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br. J. Dermatol. 2008, 159:1092-1102.
26. Horowitz M., Krueger G., Bell G., Huang S., Wyres M., Chen F. ABX-IL8 in the treatment of psoriasis: clinical results. J. Investig. Dermatol. 2002, 119:239. (Abstract).
27. Peric M., Koglin S., Kim S.M., Morizane S., Besch R., Prinz J.C., Ruzicka T., Gallo R.L., Schauber J. IL-17A enhances vitamin D3-induced expression of cathelicidin antimicrobial peptide in human keratinocytes. J. Immunol. 2008, 181:8504-8512.
28. Ganguly D., Chamilos G., Lande R., Gregorio J., Meller S., Facchinetti V., Homey B., Barrat F.J., Zal T., Gilliet M. Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. J. Exp. Med. 2009, 206:1983-1994.
29. Shen F., Hu Z., Goswami J., Gaffen S.L. Identification of common transcriptional regulatory elements in interleukin-17 target genes. J. Biol. Chem. 2006, 281:24138-24148.
30. Ma H.L., Liang S., Li J., Napierata L., Brown T., Benoit S., Senices M., Gill D., Dunussi-Joannopoulos K., Collins M., Nickerson-Nutter C., Fouser L.A., Young D.A. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J. Clin. Invest. 2008, 118:597-607.
31. Liang S.C., Tan X.Y., Luxenberg D.P., Karim R., Dunussi-Joannopoulos K., Collins M., Fouser L.A. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J. Exp. Med. 2006, 203:2271-2279.
32. Nograles K.E., Zaba L.C., Shemer A., Fuentes-Duculan J., Cardinale I., Kikuchi T., Ramon M., Bergman R., Krueger J.G., Guttman-Yassky E. IL-22-producing "T22" T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. J. Allergy Clin. Immunol. 2009, 123:1244-1252. e1242.
33. Trifari S., Kaplan C.D., Tran E.H., Crellin N.K., Spits H. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat. Immunol. 2009, 10:864-871.
34. Duhen T., Geiger R., Jarrossay D., Lanzavecchia A., Sallusto F. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat. Immunol. 2009, 10:857-863.
35. Ramirez J.M., Brembilla N.C., Sorg O., Chicheportiche R., Matthes T., Dayer J.M., Saurat J.H., Roosnek E., Chizzolini C. Activation of the aryl hydrocarbon receptor reveals distinct requirements for IL-22 and IL-17 production by human T helper cells. Eur. J. Immunol. 2010, 40:2450-2459.
36. Szabo S.K., Hammerberg C., Yoshida Y., Bata-Csorgo Z., Cooper K.D. Identification and quantitation of interferon-gamma producing T cells in psoriatic lesions: localization to both CD4+ and CD8+ subsets. J. Invest. Dermatol. 1998, 111:1072-1078.
37. Austin L.M., Ozawa M., Kikuchi T., Walters I.B., Krueger J.G. The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J. Invest. Dermatol. 1999, 113:752-759.
38. Trepicchio W.L., Ozawa M., Walters I.B., Kikuchi T., Gilleaudeau P., Bliss J.L., Schwertschlag U., Dorner A.J., Krueger J.G. Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. J. Clin. Invest. 1999, 104:1527-1537.
39. Reich K., Garbe C., Blaschke V., Maurer C., Middel P., Westphal G., Lippert U., Neumann C. Response of psoriasis to interleukin-10 is associated with suppression of cutaneous type 1 inflammation, downregulation of the epidermal interleukin-8/CXCR2 pathway and normalization of keratinocyte maturation. J. Invest. Dermatol. 2001, 116:319-329.
40. Ghoreschi K., Thomas P., Breit S., Dugas M., Mailhammer R., van Eden W., van der Zee R., Biedermann T., Prinz J., Mack M., Mrowietz U., Christophers E., Schlondorff D., Plewig G., Sander C.A., Rocken M. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat. Med. 2003, 9:40-46.
41. Abrams J.R., Kelley S.L., Hayes E., Kikuchi T., Brown M.J., Kang S., Lebwohl M.G., Guzzo C.A., Jegasothy B.V., Linsley P.S., Krueger J.G. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J. Exp. Med. 2000, 192:681-694.
42. Abrams J.R., Lebwohl M.G., Guzzo C.A., Jegasothy B.V., Goldfarb M.T., Goffe B.S., Menter A., Lowe N.J., Krueger G., Brown M.J., Weiner R.S., Birkhofer M.J., Warner G.L., Berry K.K., Linsley P.S., Krueger J.G., Ochs H.D., Kelley S.L., Kang S. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J. Clin. Invest. 1999, 103:1243-1252.
43. Chamian F., Lin S.L., Lee E., Kikuchi T., Gilleaudeau P., Sullivan-Whalen M., Cardinale I., Khatcherian A., Novitskaya I., Wittkowski K.M., Krueger J.G., Lowes M.A. Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis. J. Transl. Med. 2007, 5:27.
44. Krueger G.G., Papp K.A., Stough D.B., Loven K.H., Gulliver W.P., Ellis C.N. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J. Am. Acad. Dermatol. 2002, 47:821-833.
45. Ortonne J.P., Lebwohl M., Em Griffiths C. Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis. Eur. J. Dermatol. 2003, 13:117-123.
46. Chamian F., Lowes M.A., Lin S.L., Lee E., Kikuchi T., Gilleaudeau P., Sullivan-Whalen M., Cardinale I., Khatcherian A., Novitskaya I., Wittkowski K.M., Krueger J.G. Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc. Natl Acad. Sci. USA 2005, 102:2075-2080.
47. Krueger G.G., Ellis C.N. Alefacept therapy produces remission for patients with chronic plaque psoriasis. Br. J. Dermatol. 2003, 148:784-788.
48. Vugmeyster Y., Kikuchi T., Lowes M.A., Chamian F., Kagen M., Gilleaudeau P., Lee E., Howell K., Bodary S., Dummer W., Krueger J.G. Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin. Clin. Immunol. 2004, 113:38-46.
49. Guttman-Yassky E., Vugmeyster Y., Lowes M.A., Chamian F., Kikuchi T., Kagen M., Gilleaudeau P., Lee E., Hunte B., Howell K., Dummer W., Bodary S.C., Krueger J.G. Blockade of CD11a by efalizumab in psoriasis patients induces a unique state of T-cell hyporesponsiveness. J. Invest. Dermatol. 2008, 128:1182-1191.
50. Gordon K.B., Papp K.A., Hamilton T.K., Walicke P.A., Dummer W., Li N., Bresnahan B.W., Menter A. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003, 290:3073-3080.
51. Gottlieb A.B., Krueger J.G., Wittkowski K., Dedrick R., Walicke P.A., Garovoy M. Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch. Dermatol. 2002, 138:591-600.
52. Carey W., Glazer S., Gottlieb A.B., Lebwohl M., Leonardi C., Menter A., Papp K., Rundle A.C., Toth D. Relapse, rebound, and psoriasis adverse events: an advisory group report. J. Am. Acad. Dermatol. 2006, 54:S171-S181.
53. Sterry W., Bagot M., Ferrandiz C., Kragballe K., Papp K., Stingl G. Immunosuppressive therapy in dermatology and PML. J. Dtsch Dermatol. Ges. 2009, 7:5.
54. Eyerich S., Eyerich K., Pennino D., Carbone T., Nasorri F., Pallotta S., Cianfarani F., Odorisio T., Traidl-Hoffmann C., Behrendt H., Durham S.R., Schmidt-Weber C.B., Cavani A. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J. Clin. Invest. 2009, 119:3573-3585.
55. A. Chiricozzi, E. Guttman-Yassky, M. Suarez-Farinas, K.E. Nograles, S. Tian, I. Cardinale, S. Chimenti, J.G. Krueger, Integrative Responses to IL-17 and TNF-alpha in Human Keratinocytes Account for Key Inflammatory Pathogenic Circuits in Psoriasis, J. Invest. Dermatol. 131 (2011) 677-687.
56. Oh C.J., Das K.M., Gottlieb A.B. Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J. Am. Acad. Dermatol. 2000, 42:829-830.
57. Reich K., Nestle F.O., Papp K., Ortonne J.P., Evans R., Guzzo C., Li S., Dooley L.T., Griffiths C.E. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005, 366:1367-1374.
58. Papp K.A., Tyring S., Lahfa M., Prinz J., Griffiths C.E., Nakanishi A.M., Zitnik R., van de Kerkhof P.C., Melvin L. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br. J. Dermatol. 2005, 152:1304-1312.
59. Menter A., Tyring S.K., Gordon K., Kimball A.B., Leonardi C.L., Langley R.G., Strober B.E., Kaul M., Gu Y., Okun M., Papp K. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J. Am. Acad. Dermatol. 2008, 58:106-115.
60. W.G. Dixon, K.L. Hyrich, K.D. Watson, M. Lunt, J. Galloway, A. Ustianowski, D.P. Symmons, Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR), Ann Rheum Dis 69 (2010) 522-528.
61. Mariette X., Tubach F., Bagheri H., Bardet M., Berthelot J.M., Gaudin P., Heresbach D., Martin A., Schaeverbeke T., Salmon D., Lemann M., Hermine O., Raphael M., Ravaud P. Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. Ann. Rheum. Dis. 2010, 69:400-408.
62. Zaba L.C., Suarez-Farinas M., Fuentes-Duculan J., Nograles K.E., Guttman-Yassky E., Cardinale I., Lowes M.A., Krueger J.G. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J. Allergy Clin. Immunol. 2009, 124. 1022-1010.
63. Wong M., Ziring D., Korin Y., Desai S., Kim S., Lin J., Gjertson D., Braun J., Reed E., Singh R.R. TNFalpha blockade in human diseases: mechanisms and future directions. Clin. Immunol. 2008, 126:121-136.
64. Leonardi C.L., Kimball A.B., Papp K.A., Yeilding N., Guzzo C., Wang Y., Li S., Dooley L.T., Gordon K.B. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008, 371:1665-1674.
65. Papp K.A., Langley R.G., Lebwohl M., Krueger G.G., Szapary P., Yeilding N., Guzzo C., Hsu M.C., Wang Y., Li S., Dooley L.T., Reich K. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008, 371:1675-1684.
66. Griffiths C.E., Strober B.E., van de Kerkhof P., Ho V., Fidelus-Gort R., Yeilding N., Guzzo C., Xia Y., Zhou B., Li S., Dooley L.T., Goldstein N.H., Menter A. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N. Engl. J. Med. 2010, 362:118-128.
67. Kimball A.B., Gordon K.B., Langley R.G., Menter A., Chartash E.K., Valdes J. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch. Dermatol. 2008, 144:200-207.
68. A.A. Saad, D.M. Ashcroft, K.D. Watson, D.P. Symmons, P.R. Noyce, K.L. Hyrich, Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register, Rheumatology (Oxford) 49 (2010) 697-705.